After shivering through more than a year of “capital winter,” Chinese drug makers are finally feeling the thaw of spring, encouraging unprofitable companies to return their eyes to Hong Kong listings. Sichuan Kelun Pharmaceutical (002422.SZ) became the latest to join the trend last week, as its Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. subsidiary filed to list in Hong Kong, with Goldman Sachs and Citic Securities as sponsors.
作者莫莉，本文仅代表个人观点。
您已阅读6%（451字），剩余94%（7359字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。